A new highly sensitive real-time quantitative-PCR method for detection of BCR-ABL1 to monitor minimal residual disease in chronic myeloid leukemia after discontinuation of imatinib
Y. Tabe, H. Kitamura, K. Tsuchiya, M. Yuri, T. Ai, S. Misawa, T. Horii, A. Ohsaka, S. Kimura
This paper develops a new in-house RQ-PCR method for detecting BCR-ABL1 transcripts in CML patients, showing higher sensitivity than commercial methods for monitoring minimal residual disease.
bioRxiv · Oct 29, 2018Cancer Biology